基本信息
浏览量:0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
My lab is interested in elucidating the molecular and cellular mechanisms involved in tumor-mediated immune suppression and cancer immunotherapy resistance. Our overriding hypothesis is that tumor cells and/or their associated stromal elements elicit soluble factors that tolerize local dendritic cell populations and/or recruit other immunosuppressive cell populations to the tumor bed; thereby, interfering with the generation of an effective anti-tumor immune response. This work has both basic and translational significance in that it is capable of providing 1. novel pharmacological targets for enhancing anti-tumor immunity and 2. much needed biomarkers for guiding the management of cancer patients with immunotherapies. We perform these investigations utilizing both transgenic murine models as well as clinical specimens derived from cancer patients undergoing immunotherapy. We focus these studies on melanoma, non-small cell lung cancer, pancreatic cancer, and colon cancer.
We currently have the following ongoing projects in our lab:
1. Investigating mechanisms by which developing cancers alter the metabolism of local dendritic cells thereby hijacking this antigen-presenting cell population to generate an immunotolerant tumor microenvironment.
2. Identifying soluble factors expressed by cancers which manipulate local dendritic cell function to drive regulatory T cell differentiation within the tumor microenvironment as well as any potential oncogenic signaling pathways driving this process.
3. Characterizing mechanisms of innate and adaptive resistance mechanisms to checkpoint inhibitor therapies.
4. Examining the role of the tumor stroma in interfering with immunotherapy efficacy.
5. Design and development of novel dendritic cell-based vaccine strategies
We currently have the following ongoing projects in our lab:
1. Investigating mechanisms by which developing cancers alter the metabolism of local dendritic cells thereby hijacking this antigen-presenting cell population to generate an immunotolerant tumor microenvironment.
2. Identifying soluble factors expressed by cancers which manipulate local dendritic cell function to drive regulatory T cell differentiation within the tumor microenvironment as well as any potential oncogenic signaling pathways driving this process.
3. Characterizing mechanisms of innate and adaptive resistance mechanisms to checkpoint inhibitor therapies.
4. Examining the role of the tumor stroma in interfering with immunotherapy efficacy.
5. Design and development of novel dendritic cell-based vaccine strategies
研究兴趣
论文共 103 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Science immunologyno. 95 (2024)
bioRxiv the preprint server for biology (2024)
Nagendra Yarla, Kaylee Howell,Y-Van Nguyen, Donna Niedwiecki,Hope Uronis,John Strickler,Nicholas C. DeVito,Bala Theivanthiran,Brent A. Hanks
Cancer Researchno. 6_Supplement (2024): 7521-7521
Annals of surgeryno. 6 (2023): E1306-E1312
Cancer researchno. 7_Supplement (2023): 2892-2892
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
Elle C. Moore,Gerard C. Blobe,Nicholas C. Devito,Brent A. Hanks,Michael R. Harrison,Christopher J. Hoimes,Jingquan Jia,Michael A. Morse, Parvathy Jayaprakasan, Andrew MacKelfresh,Hillary Mulder,Adam J. Hockenberry,
加载更多
作者统计
#Papers: 104
#Citation: 2542
H-Index: 27
G-Index: 50
Sociability: 8
Diversity: 3
Activity: 46
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn